Asia Tech Wire (Oct 10) -- The Swiss Competition Commission (COMCO) announced on Thursday the termination of its investigation into pharmaceutical giant Novartis without consequences.

In September 2022, COMCO opened an investigation into Novartis, with the aim of determining whether the company intended to illegally protect one of its dermatology drugs by filing various patent infringement lawsuits.

The results of the investigation indicated that Novartis' behavior was common practice in the field of patent law, and that there was no substantiation of the aforementioned indications of an unlawful restriction of competition.

Therefore, COMCO terminated the investigation against Novartis.